Profile data is unavailable for this security.
About the company
Lasa Supergenerics Limited is an India-based company, which is engaged in the business of manufacturing active pharmaceutical ingredients (API) bulk drugs products. The Company is engaged in the business of manufacturing, trading, producing, processing, preparing, treating chemicals, API, pharmaceuticals, drugs, and others. It is specialized in catalyst chemistry and manufactures anthelmintic/ veterinary API products with the production capabilities and product categories in India. The Company's products include API products, other API products, animal feed ingredients and reagents for therapeutic use. Its API products include Fenbendazole, Toldimphos sodium, Cyromazine, Albendazole, Riclabendazole, Rafoxanide, Ornidazole, 2,6-Diiodo-4-Nitrophenol, Ricobendazole, Oxfendazole, Closantel Base, Closantel sodium, Nitroxynil, Halquinol, and Oxyclozanide. The Company's manufacturing facility is located at Chiplun, Maharashtra.
- Revenue in INR (TTM)1.05bn
- Net income in INR-195.13m
- Incorporated2016
- Employees77.00
- LocationLasa Supergenerics LtdB/207, CITI Point, AndheriKurla Road, Andheri (East)MUMBAI 400059IndiaIND
- Phone+91 2 145232101
- Websitehttps://lasalabs.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Biofil Chemicals and Pharmaceuticals Ltd | 460.45m | 6.34m | 1.22bn | -- | 188.74 | -- | 119.22 | 2.65 | 0.3978 | 0.3978 | 28.96 | -- | -- | -- | -- | -- | -- | 2.74 | -- | 5.36 | 4.94 | 9.99 | 1.38 | 2.80 | -- | 7.63 | -- | -- | 33.29 | 11.60 | 26.55 | 8.02 | -56.15 | -- |
Ind Swift Ltd | 4.68bn | 401.08m | 1.23bn | 1.67k | 3.07 | -- | 1.87 | 0.2636 | 7.42 | 7.42 | 86.37 | -- | -- | -- | -- | -- | -- | -0.902 | -- | -- | 45.63 | 45.72 | 8.58 | -1.44 | -- | 0.1318 | -- | -- | 22.21 | 11.68 | -45.34 | 11.68 | 15.24 | -- |
Lasa Supergenerics Ltd | 1.05bn | -195.13m | 1.35bn | 77.00 | -- | -- | -- | 1.29 | -3.92 | -3.92 | 20.94 | -- | -- | -- | -- | 13,586,300.00 | -- | -3.86 | -- | -5.34 | 26.41 | 32.53 | -18.65 | -5.30 | -- | -4.49 | -- | -- | -19.47 | -9.26 | 43.73 | -- | -- | -- |
Vaidya Sane Ayurved Laboratories Ltd | 993.31m | 19.80m | 1.49bn | 636.00 | 84.90 | 2.67 | 28.94 | 1.50 | 1.66 | 1.66 | 78.54 | 52.89 | 1.58 | 6.83 | 15.11 | 1,561,813.00 | 3.16 | 4.83 | 4.02 | 7.49 | 74.12 | 70.91 | 2.00 | 2.53 | 2.11 | 5.49 | 0.0293 | -- | 0.1638 | 9.71 | -59.02 | 31.91 | 4.43 | -- |
Sotac Pharmaceuticals Ltd | 1.10bn | 37.21m | 1.52bn | 89.00 | 40.75 | -- | 21.34 | 1.38 | 3.37 | 3.37 | 99.70 | -- | -- | -- | -- | -- | -- | -- | -- | -- | 21.53 | -- | 3.38 | -- | -- | 2.75 | -- | -- | 79.07 | -- | -20.38 | -- | -- | -- |